Skip to main content

Advertisement

SpringerLink
Log in

Cutaneous T-cell lymphoma/leukemia

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Effective treatment for cutaneous T-cell lymphomas (CTCL) requires an accurate and specific diagnosis based on the clinical presentation combined with evaluation of the histopathology, immunophenotyping, and gene rearrangement studies. Careful clinical and pathologic evaluation in centers familiar with the diverse forms of CTCL is most valuable for determining treatment options. The goals of treatment in mycosis fungoides (MF), which afflicts more than 50% of patients with CTCL, are the relief of symptoms and improvement in cosmetics. Despite some uncontrolled clinical trial results that have been reported to suggest “cures” in this disease, the general perception remains that this disease is not curable with standard therapies available today. Treatment is divided into topical (skin-directed) and systemic therapy. The most active systemic agent for the treatment of MF remains interferon-α, although many new modalities have recently been approved for the treatment of CTCL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Kuzel TM, Guitart J, Rosen ST: Cutaneous T-cell Lymphomas. In Hematology: Basic Principles and Practice. Edited by Hoffman R, Benz Jr. EJ, Shattil SJ, et al. 1372–1387. A thorough summary of CTCL.

  2. Willemze R, Beljaards RC, Meijer CJ, et al.: Classification of primary cutaneous lymphomas. Historical overview and perspectives. Dermatology 1994, 189(suppl 2):8–15. Excellent discussion of CTCL classification.

    Article  PubMed  Google Scholar 

  3. Willemze R, Kerl H, Sterry W, et al.: EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997, 90:354–371.

    PubMed  CAS  Google Scholar 

  4. Weinstock MA, Horm JW: Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiology. JAMA 1988, 260:42–46.

    Article  PubMed  CAS  Google Scholar 

  5. Rook AH, Heald P: The immunopathogenesis of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995, 9:997–1010. A thorough summary of immunopathogenesis of CTCL.

    PubMed  CAS  Google Scholar 

  6. Weinstock MA, Horm JW: Population-based estimate of survival and determinants of prognosis in patients with mycosis fungoides. Cancer 1988, 62:1658–1661.

    Article  PubMed  CAS  Google Scholar 

  7. Kaye FJ, Bunn PA, Steinberg SM, et al.: A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989, 321:1784–1790.

    Article  PubMed  CAS  Google Scholar 

  8. Herrmann JJ, Roenigk HH, Hurria A, et al.: Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol 1995, 33:234–242. Good review of PUVA.

    Article  PubMed  CAS  Google Scholar 

  9. Jones GW, Hoppe RT, Glatstein E: Electron beam treatment for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995, 9:1057–1076. Good review of TSEBT.

    PubMed  CAS  Google Scholar 

  10. Reddy S, Parker CM, Shidnia H, et al.: Total skin electron beam radiation therapy for mycosis fungoides. Am J Clin Oncol 1992, 15:119–124.

    Article  PubMed  CAS  Google Scholar 

  11. Hoppe RT, Cox RS, Fuks Z, et al.: Electron-beam therapy for mycosis fungoides: the Stanford University experience. Cancer Treat Rep 1979, 63:691–700.

    PubMed  CAS  Google Scholar 

  12. Quiros PA, Ones GW, Kacinski BM, et al.: Total skin electron beam therapy followed by adjuvant psoralen/ ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys 1997, 38:1027–1035.

    Article  PubMed  CAS  Google Scholar 

  13. Hoppe RT, Abel EA, Deneau DG, et al.: Mycosis fungoides: management with topical nitrogen mustard. J Clin Oncol 1987, 5:1796–1803.

    PubMed  CAS  Google Scholar 

  14. Ramsay DL, Ed M, Halperin PS, et al.: Topical mechlorethamine therapy for early stage mycosis fungoides. J Am Acad Dermatol 1988, 19:684–691.

    PubMed  CAS  Google Scholar 

  15. Price NM, Hoppe RT, Deneau DG: Ointment-based mechlorethamine treatment for mycosis fungoides. Cancer 1983, 52:2214–2219.

    Article  PubMed  CAS  Google Scholar 

  16. Zackheim HS: Topical carmustine (BCNU) for patch/ plaque mycosis fungoides. Semin Dermatol 1994, 13:202–206.

    PubMed  CAS  Google Scholar 

  17. Rosen ST, Foss FM: Chemotherapy for mycosis fungoides and the Sézary syndrome. Hematol Oncol Clin North Am 1995, 9:1109–1116.

    PubMed  CAS  Google Scholar 

  18. Broder S, Bunn PA Jr: Cutaneous T-cell lymphomas. Semin Oncol 1980, 7:310–331.

    PubMed  CAS  Google Scholar 

  19. Zackheim HS, Epstein EH: Low-dose methotrexate for the Sézary Syndrome. J Am Acad Dermatol 1989, 21:757–762.

    Article  PubMed  CAS  Google Scholar 

  20. Kuzel TM, Hurria A, Samuelson E, et al.: Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood 1996, 87:906–911.

    PubMed  CAS  Google Scholar 

  21. Grever MR, Bisaccia E, Scarborough DA, et al.: An Investigation of 2’-deoxycoformycin in the treatment of cutaneous T-cell lymphoma. Blood 1983, 61:279–282.

    PubMed  CAS  Google Scholar 

  22. Cummings FJ, Kim K, Neiman RS, et al.: Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease. J Clin Oncol 1991, 9:565–571.

    PubMed  CAS  Google Scholar 

  23. Dang-Vu AP, Olsen EA, Vollmer RT, et al.: Treatment of cutaneous T-cell lymphoma with 2’-deoxycoformycin (pentostatin). J Am Acad Dermatol 1988, 19:692–698.

    PubMed  CAS  Google Scholar 

  24. Bunn PA, Ihde DC, Foon KA: The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas. Cancer 1986, 57:1689–1695.

    Article  PubMed  Google Scholar 

  25. Olsen EA, Rosen ST, Vollmer RT, et al.: Interferon alfa-2a in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1989, 20:395–407.

    Article  PubMed  CAS  Google Scholar 

  26. Olsen EA, Bunn PA: Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995, 9:1089–1107.

    PubMed  CAS  Google Scholar 

  27. Kuzel TM, Roenigk HH, Samuelson E, et al.: Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol 1995, 13:257–263.

    PubMed  CAS  Google Scholar 

  28. Stadler R, Otte HG, Luger T, et al.: Prospective randomized multicenter clinical trial on the use of interferon a-2a plus acitretin versus interferon a-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998, 92:3578–3581.

    PubMed  CAS  Google Scholar 

  29. Nichols J, Foss F, Kuzel TM, et al.: Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Eur J Cancer 1997, 33(suppl 1):34–36.

    Article  Google Scholar 

  30. Saleh MN, LeMaistre CF, Kuzel TM, et al.: Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol 1998, 39:63–73. Report of recently approved DAB389IL-2.

    Article  PubMed  CAS  Google Scholar 

  31. Kuzel T, Olsen E, Martin A, et al.: Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak) for the treatment of mycosis fungoides. ASH 1997, Abstract #2607.

  32. Edelson R, Berger C, Gasparro F, et al.: Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N Engl J Med 1987, 316:297–303.

    Article  PubMed  CAS  Google Scholar 

  33. Edelson R, Heald, Perez, et al.: Photopheresis update. Prog Dermatol 1991, 25:1–6.

    Google Scholar 

  34. Fraser-Andrews E, Seed P, Whittaker S, et al.: Extracorporeal photopheresis in Sézary syndrome: no significant effect in the survival of 44 patients with a peripheral blood T-cell clone. Arch Dermatol 1998, 134:1001–1005.

    Article  PubMed  CAS  Google Scholar 

  35. Hymes K, Duvic M, Heald P, et al.: Oral bexarotene benefits patients with refractory advanced stage CTCL. ASH 1999, Abstract #425.

  36. Siegel RS, Martone B, Guitart J, et al.: Phase II trial of ALL-trans retinoic acid (ATRA) in the treatment of relapsed/refractory mycosis fungoides/Sézary syndrome (MF/SS). ASH 1999, Abstract #423.

Download references

Author information

Authors and Affiliations

  1. Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, 676 N. St. Clair, Suite 850, 60611, Chicago, IL, USA

    Richard S. Siegel MD & Timothy M. Kuzel MD

Authors
  1. Richard S. Siegel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timothy M. Kuzel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Siegel, R.S., Kuzel, T.M. Cutaneous T-cell lymphoma/leukemia. Curr. Treat. Options in Oncol. 1, 43–50 (2000). https://doi.org/10.1007/s11864-000-0014-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-000-0014-0

Keywords

Search

Navigation